Acute promyelocytic leukemia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

A limited number of cost-effective studies have been done. In summary, these studies showed that all-trans retinoic acid-based therapy is more cost effective than chemotherapy.

Cost-effectiveness of therapy

A limited number of cost-effectiveness studies have been performed in acute promyelocytic leukemia. One comprehensive cost-effective analysis studied the costs of therapy.

The combination of all-trans retinoic acid plus idarubicin was more cost-effective than the combination of all-trans retinoic acid plus cytarabine plus additional chemotherapy.^[1]
- The incremental cost-effective ratio for all-trans retinoic acid plus idarubicin was $2933 per life year saved and $3122 per quality-adjusted life year gained.^[1]
The combination of all-trans retinoic acid plus arsenic trioxide was more cost-effective than all-trans retinoic acid plus idarubicin.^[1]
- The incremental cost-effective ratio for all-trans retinoic acid plus arsenic trioxide was $4512 per life year saved and $5614 per quality-adjusted life year gained.^[1]

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M; et al. (2015). “Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States”. Clin Lymphoma Myeloma Leuk. 15 (12): 771–7. doi:10.1016/j.clml.2015.07.634. PMC 5028894. PMID 26361645.

Template:WH Template:WS

[pmid26361645-1] 1.0 ^1.1 ^1.2 ^1.3 Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M; et al. (2015). “Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States”. Clin Lymphoma Myeloma Leuk. 15 (12): 771–7. doi:10.1016/j.clml.2015.07.634. PMC 5028894. PMID 26361645.

[1]